摘要
酒精是死亡和残疾的主要风险因素。酒精依赖(AD)的治疗因其变数众多而复杂;无论如何,都必须考虑到酒精依赖(AD)的类型、内在合并症和任何精神疾病的存在。肝脏疾病是酒精性肝损害最普遍的原因之一。45%的肝硬化的死亡与酒精相关。因此,酒精依赖(AD)的治疗通常必须处理或多或少的严重的肝脏疾病,从而影响抗瘾药物的选择。慢性肝病很多见,并在相当大比例范围的病例中病毒感染与肝细胞癌(HCC)相关,显然肝病学家应当利用非肝毒性分子物。在轻度肝病的情况下,所有可用的药物可能被使用,但我们建议谨慎应用,由于酒精有害的滥用,肝脏通常是很容易损害的。晚期肝病的治疗选择甚少。社会心理的方法,如参加支持小组可以是首选。美他多辛,阿坎酸和巴氯芬可用在肝硬化代偿期有或无肝细胞癌(HCC)的病例,或无肝硬化的肝细胞癌(HCC)病例。巴氯芬是至今为止经过验定可用在肝硬化失代偿期的唯一药物。对于与酒精相关的肝脏疾病,尤其是对肝移植的项目,组成肝-酒精相关专家的专业团队也是必要的。
关键词: 酒精依赖,酒精性肝病,抗瘾药物、支持小组。
图形摘要
Current Drug Targets
Title:Liver Disease and Hepatocellular Carcinoma in Alcoholics: The Role of Anticraving Therapy
Volume: 17 Issue: 2
Author(s): Paolo Borro, Silvia Leone and Gianni Testino
Affiliation:
关键词: 酒精依赖,酒精性肝病,抗瘾药物、支持小组。
摘要: Alcohol is the main risk factor for death and disability. The treatment of alcohol dependence (AD) is a complex activity as the variables are numerous; however, those which must necessarily be taken into account are the type of AD, the internal comorbidities and the presence of any psychiatric comorbidity. Liver problems are one of the most common causes of alcohol-related liver damage. 45% of deaths from cirrhosis are alcohol-related. Thus, the treatment of AD must often deal with a more or less severe liver disease, which influences the choice of anticraving drug. As chronic liver disease is often present, and as in a substantial proportion of cases, because there is a correlation with viral infections or with hepatocellular carcinoma (HCC), it is clear that hepatologists should make use of nonhepatotoxic molecules. In cases of mild liver disease, all available drugs might be used, but we recommend caution because the liver is usually fragile due to the harmful abuse of alcohol. In the advanced liver disease, the choice of treatment is reduced. A psychosocial approach such as attending support groups could be the first choice. In cases of compensated cirrhosis with or without HCC, or in cases of HCC without cirrhosis, metadoxine, acamprosate and baclofen can be used. In decompensated forms the only drug tested to date has been baclofen. In alcohol-related liver disease a professional team with hepato-alcohologists is also necessary, especially for liver transplantation programs.
Export Options
About this article
Cite this article as:
Paolo Borro, Silvia Leone and Gianni Testino , Liver Disease and Hepatocellular Carcinoma in Alcoholics: The Role of Anticraving Therapy, Current Drug Targets 2016; 17 (2) . https://dx.doi.org/10.2174/1389450116666150518102204
DOI https://dx.doi.org/10.2174/1389450116666150518102204 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Related Books

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers